Comprehensive Snapshot of Precision Oncology Market Research Report, Including Regional and Country Analysis in Brief.
Industry: Healthcare
Delivery Timelines: Please Contact Sales
Published Date: June-2025
Format: PPT*, PDF, EXCEL
Number of Pages: 198
ID: PMRREP35389
The global precision oncology market is projected to witness a CAGR of 10.8% from 2025 to 2032. It is anticipated to increase from US$132.3 Mn recorded in 2025 to a staggering US$280.3 Mn by 2032.
The global precision oncology market is revolutionizing cancer treatment by leveraging genomic profiling, targeted therapies, and AI-driven diagnostics. With rising cancer incidence and advancements in next-generation sequencing (NGS), personalized medicine is becoming the standard. The market is expanding due to increasing biomarker-based drug development and regulatory approvals for companion diagnostics. Key players are investing in liquid biopsy, AI-driven analytics, and immunotherapies to enhance patient outcomes.
Key Industry Highlights:
|
Global Market Attribute |
Key Insights |
|
Market Size (2025E) |
US$ 132.3 Mn |
|
Market Value Forecast (2032F) |
US$ 280.3 Mn |
|
Projected Growth (CAGR 2025 to 2032) |
10.8% |
|
Historical Market Growth (CAGR 2019 to 2024) |
8.2% |
The evolution of companion diagnostics (CDx) in precision oncology is shifting from conventional single-gene tests to comprehensive molecular profiling that integrates next-generation sequencing (NGS), whole-exome sequencing (WES), and transcriptomics. This advancement enables a more holistic understanding of tumor biology, allowing clinicians to identify multiple actionable mutations within a single test rather than relying on individual biomarker assessments. By using multi-gene panels and pan-cancer profiling approaches, CDx expands drug-treatment matches beyond traditional targeted therapies, unlocking novel combinations and repurposed drugs for rare and complex malignancies.
A key breakthrough in next-generation CDx is its role in matching patients with emerging immunotherapies and combination treatments. Instead of focusing solely on single mutations, modern CDx platforms analyze tumor mutational burden (TMB), microsatellite instability (MSI), and RNA expression profiles, helping oncologists select the most effective immunotherapy regimens. Additionally, the rise of liquid biopsy-based CDx is improving accessibility by offering non-invasive testing solutions for patients who cannot undergo tissue biopsies.
Variability in stool sample collection and handling presents a significant challenge in the adoption of precision oncology, as improper collection techniques can lead to inaccurate results, reducing the reliability of the test. Unlike blood or urine samples, stool consistency and composition can vary significantly among patients, affecting calprotectin concentration measurements. Factors such as diet, hydration levels, and transit time in the gut can alter the sample composition, making standardization difficult. Additionally, patients may struggle with proper sample collection, leading to contamination, insufficient sample volume, or degradation of biomarkers before laboratory analysis.
Improper storage and transportation further exacerbate the issue. Since fecal calprotectin is a protein susceptible to degradation, delays in sample processing or exposure to temperature fluctuations can result in false-negative or misleading results. This inconsistency undermines physician confidence in the test, prompting some healthcare providers to favor more invasive diagnostic methods like endoscopy. Moreover, laboratory discrepancies in extraction protocols and analysis methods create further variability, limiting the widespread acceptance of precision oncologying as a diagnostic standard.
Liquid Biopsy for Early Minimal Residual Disease (MRD) Detection in Solid Tumors represents a transformative opportunity in precision oncology. MRD refers to the small number of cancer cells that stays in a patient’s body after curative treatment, often undetectable by conventional imaging but capable of causing relapse. While MRD detection using blood-based liquid biopsies, especially through circulating tumor DNA (ctDNA) is already gaining traction in hematologic malignancies, its application in solid tumors is still emerging and holds immense potential. Technologies that enable ultra-sensitive detection of tumor-specific mutations or methylation patterns from a simple blood draw can revolutionize post-treatment monitoring, recurrence risk assessment, and adjuvant therapy decision-making. This opportunity is driven by the rising need for non-invasive, real-time surveillance tools in cancers such as lung, colorectal, breast, and pancreatic cancers, where residual disease is often missed until overt relapse occurs.
Pharmaceutical companies are also showing increasing interest in MRD as a surrogate endpoint for clinical trials. However, challenges remain, including assay standardization, tumor heterogeneity, and regulatory clarity. Players who can overcome these barriers with high-sensitivity, tumor-informed platforms have the potential to shape the future of cancer care by making personalized post-treatment management a standard of care in solid tumors.
Enzyme-linked immunosorbent assay (ELISA) leads the technique segment in the precision oncology market as a service-based market due to its high sensitivity, cost-effectiveness, and ability to handle large sample volumes efficiently. ELISA offers a standardized and automated approach, making it the preferred choice for diagnostic laboratories and service providers. Unlike lateral flow assays, which may provide qualitative or semi-quantitative results, ELISA delivers precise and reproducible quantitative measurements of fecal calprotectin levels, improving diagnostic accuracy for inflammatory bowel diseases (IBD).
Furthermore, ELISA-based precision oncology is compatible with high-throughput screening, enabling service providers to process multiple samples simultaneously, reducing turnaround time and operational costs.
Inflammatory Bowel Disease (IBD) leads the indication segment in the precision oncology market as a service-based market due to its growing global prevalence and the need for noninvasive diagnostic and monitoring solutions. Unlike irritable bowel syndrome (IBS) or other gastrointestinal disorders, IBD, comprising Crohn’s disease and ulcerative colitis requires frequent disease activity assessment to guide treatment decisions. Fecal calprotectin testing is a preferred option as it differentiates between inflammatory and non-inflammatory conditions, reducing unnecessary endoscopic procedures.
Additionally, IBD management relies on continuous monitoring to evaluate treatment efficacy and predict disease flares, making precision oncology a cost-effective and patient-friendly alternative to repeated invasive tests.
North America dominates the precision oncology market as a service-based industry due to its advanced healthcare infrastructure, high disease prevalence, and increasing reliance on diagnostic outsourcing. The region has a well-established network of reference laboratories and diagnostic service providers, allowing for widespread accessibility to precision oncology without the need for in-house hospital diagnostics. The rising incidence of inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, has driven demand for non-invasive biomarkers, with fecal calprotectin emerging as a preferred diagnostic tool.
According to the CDC, in 2024, IBD affected approximately 3 million adults in the U.S., creating a strong market for outsourced diagnostic services. Additionally, favorable reimbursement policies from private and public insurers encourage clinicians to recommend precision oncology, boosting service-based testing volumes.
Europe is the second-leading region in the precision oncology market due to a combination of strong healthcare infrastructure, high prevalence of inflammatory bowel diseases (IBD), and government-backed reimbursement policies. Countries such as Germany, the UK, and France have well-established diagnostic services that enable the widespread adoption of precision oncology, particularly in primary and secondary healthcare settings. The growing burden of Crohn’s disease and ulcerative colitis in Europe, with an estimated prevalence of over 3.4 million cases, has driven demand for non-invasive biomarkers such as fecal calprotectin, reducing the need for more invasive diagnostic procedures such as endoscopy. Additionally, Europe's stringent clinical guidelines, such as those issued by the European Crohn’s and Colitis Organization (ECCO), encourage the routine use of precision oncology for monitoring disease progression, further accelerating market adoption.
Asia Pacific is rapidly emerging as a key market for precision oncology services, driven by the increasing prevalence of gastrointestinal disorders and the rising burden of inflammatory bowel disease (IBD). The shift towards early disease detection and non-invasive diagnostics has fueled demand for precision oncology particularly in urban centers where healthcare accessibility is improving.
Japan and South Korea lead in advanced diagnostic services due to well-established laboratory infrastructure and government-supported insurance schemes that cover biomarker-based tests. Meanwhile, India and Southeast Asian nations are experiencing strong growth due to the expansion of private diagnostic labs offering cost-effective precision oncology as a service. The increasing adoption of outsourced laboratory testing models in hospitals and clinics has further propelled market expansion, enabling faster and more efficient diagnostics.
The global precision oncology market is highly competitive, with key players focusing on expanding laboratory networks, automation, and AI-driven diagnostics. Strategic collaborations between hospitals and third-party labs continue to shape market dynamics, making innovation and cost-efficiency key differentiators.
|
Report Attribute |
Details |
|
Historical Data/Actuals |
2019 - 2024 |
|
Forecast Period |
2025 - 2032 |
|
Market Analysis Units |
Value: US$ Mn |
|
Geographical Coverage |
|
|
Segmental Coverage |
|
|
Competitive Analysis |
|
|
Report Highlights |
|
|
Customization and Pricing |
Available upon request |
By Technique
By Indication
By End-user
By Region
To know more about delivery timeline for this report Contact Sales
The global precision oncology market is estimated to increase from US$ 4,728.3 Mn in 2025 to US$ 9,623.7 Mn in 2032.
The increasing incidence of inflammatory bowel disease (IBD), Crohn’s disease, and ulcerative colitis is a major driver. Over 10 million people worldwide are affected by IBD, fueling demand for non-invasive diagnostics such as precision oncology.
The market is projected to record a CAGR of 8.9% during the forecast period from 2025 to 2032.
The growing demand for convenient and patient-friendly diagnostics is creating opportunities for home-based fecal sample collection kits. Companies can invest in telehealth integration and AI-driven analysis to enhance accessibility.
Some key players in the precision oncology market include Epitope Diagnostics Inc., Hycult Biotech, Actim, OPERON, Svar Life Science, BÜHLMANN, DRG International Inc., ALPCO, Diazyme Laboratories, and Thermo Fisher Scientific Inc.
